articleTop 10% cited
Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
Breast Cancer Research and Treatment · 2018 · Vol. 170(3) · pp. 559–567
Waqar Haque✉(Methodist Hospital)Vivek Verma(Allegheny General Hospital)Sandra S. Hatch(The University of Texas Medical Branch at Galveston)V. Suzanne Klimberg(The University of Texas Medical Branch at Galveston)E. Brian Butler(Methodist Hospital)Bin S. Teh(Methodist Hospital)
Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchCancer Cells and MetastasisBreast cancerChemotherapyMedicineOncologyNeoadjuvant therapyComplete responseMammary glandInternal medicineCancer
MeSH terms
Kaplan-Meier EstimateAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyFemaleHumansMiddle AgedNeoplasm StagingBiomarkers, TumorProportional Hazards ModelsOdds RatioTreatment Outcome
Citations
375
FWCI
8.90
field-weighted impact
References
22
Percentile
99%
vs. same field & year
Citations per year
References
The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States
Annals of Surgical Oncology · 2008 · 1,817 citations
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Journal of Clinical Oncology · 2008 · 2,876 citations
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Clinical Cancer Research · 2007 · 2,107 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.